← back to search

Jolanta M. Siller‐Matula

Medical University of Vienna · AT
Area of research
Cardiology and Cardiovascular Medicine · Internal Medicine
Research interest
Research interests include Antiplatelet Therapy and Cardiovascular Diseases, Atrial Fibrillation Management and Outcomes, Acute Myocardial Infarction Research, and Venous Thromboembolism Diagnosis and Management.
h-index
54
citations
15,473
works
287
NIH funding
primary concept
Medicine
email

Recent publications

Bleeding complications in patients with out-of-hospital cardiac arrest treated with cangrelor and oral P2Y12 inhibitors.
2026cited by 3position: contributordoi
A multicentre observational study on landiolol use, efficacy, and safety in European patients with supraventricular arrhythmia (Landi-UP).
2026cited by 2position: contributordoi
Impact of direct oral anticoagulants on target lesion revascularization rates in patients with chronic coronary syndrome.
2026cited by 1position: contributordoi
Plasma metabolomic profiling of patients with acute coronary syndrome treated with potent platelet inhibitors.
2026cited by 0position: contributordoi
Effect of Intramuscular Adrenaline on Histamine-Induced Hypotension: A Randomised Placebo-Controlled Pilot Trial.
2026cited by 0position: contributordoi
Correction: Sirtuins and regulatory miRNAs as epigenetic determinants of empagliflozin-mediated recovery after acute myocardial infarction.
2026cited by 0position: contributordoi
2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias.
2025cited by 115position: contributordoi
Definitions of clinical study outcome measures for cardiovascular diseases: the European Unified Registries for Heart Care Evaluation and Randomized Trials (EuroHeart).
2025cited by 11position: contributordoi
Antithrombotic drugs for acute coronary syndromes in women: sex-adjusted treatment and female representation in randomised clinical trials. A clinical consensus statement of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) and the ESC Working Group on Thrombosis.
2025cited by 4position: contributordoi
Impact of empagliflozin on cardiac structure and function assessed by echocardiography after myocardial infarction: a post-hoc sub-analysis of the emmy trial.
2025cited by 4position: contributordoi
Management of patients with congenital bleeding disorders and cardiac indications for antithrombotic therapy.
2025cited by 3position: contributordoi
Prediction model for leaflet thrombosis in patients undergoing transcatheter aortic valve implantation: the EFFORT study.
2025cited by 3position: contributordoi
Sirtuins and regulatory miRNAs as epigenetic determinants of empagliflozin-mediated recovery after acute myocardial infarction.
2025cited by 1position: contributordoi
The quality of care and long-term mortality of out of hospital cardiac arrest survivors after acute myocardial infarction: a nationwide cohort study.
2025cited by 1position: contributordoi
One-year clinical outcomes in patients with acute coronary syndrome treated with clopidogrel versus prasugrel versus ticagrelor: Results of the Polish Registry of Acute Coronary Syndromes (PL-ACS).
2025cited by 0position: contributordoi
Antithrombotic drugs for acute coronary syndromes in women: sex-adjusted treatment and female representation in randomised clinical trials. A clinical consensus statement of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) and the ESC Working Group on Thrombosis.
2025cited by 0position: contributordoi
Prolonged antithrombotic treatment after de-escalation of dual antiplatelet therapy in patients after acute coronary syndrome - which strategy should be applied? The ELECTRA-SIRIO 2 investigators standpoint.
2025cited by 0position: contributordoi
Early treatment with inhibitors of P2Y12 receptor in patients with ST-segment elevation myocardial infarction - 2023 ESC recommendations and scientific evidence. Is clinical evidence sufficient to suggest a move towards precision medicine? The ELECTRA-SIRIO 2 investigators' viewpoint.
2025cited by 0position: contributordoi
Maintenance therapy with a P2Y12 receptor inhibitor after cangrelor in patients with acute coronary syndrome. The ELECTRA-SIRIO 2 investigators' viewpoint.
2025cited by 0position: contributordoi
2023 ESC Guidelines for the management of acute coronary syndromes.
2024cited by 234position: contributordoi
International Consensus Statement on Platelet Function and Genetic Testing in Percutaneous Coronary Intervention
JACC: Cardiovascular Interventions 2024cited by 85position: contributordoi
Landiolol for refractory ventricular fibrillation in out-of-hospital cardiac arrest: A randomized, double-blind, placebo-controlled, pilot trial.
2024cited by 12position: contributordoi
Commissural alignment during TAVR reduces the risk of overlap to coronary ostia.
2024cited by 9position: contributordoi
Effects of empagliflozin in women and men with acute myocardial infarction: An analysis from the EMMY trial.
2024cited by 9position: contributordoi
Expression of miR-223 to predict outcomes after transcatheter aortic valve implantation.
2024cited by 5position: contributordoi
Incidence and Predictors of Worsening Renal Function in Edoxaban-Treated Atrial Fibrillation Patients Within ETNA-AF-Europe Registry
JACC: Advances 2024cited by 2position: contributordoi
Alteration of circulating ACE2-network related microRNAs in patients with COVID-19.
2024cited by 2position: contributordoi
Ticagrelor downregulates the expression of proatherogenic and proinflammatory miR125-b compared to clopidogrel: A randomized, controlled trial.
2024cited by 1position: contributordoi
The quality of care and long-term mortality of out of hospital cardiac arrest survivors after acute myocardial infarction: a nationwide cohort study
European Heart Journal - Quality of Care and Clinical Outcomes 2024cited by 1position: middledoi
Abbreviated dual antiplatelet therapy after acute coronary syndrome.
2024cited by 0position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 25 papers (2019–2026)Dirk von Lewinski · NIHR Leicester Biomedical Research Centre19 papers (2019–2026)Bernd Jilma · Universitätszahnklinik Wien15 papers (2019–2026)Jacek Kubica · University of Bydgoszcz11 papers (2019–2025)Giuseppe Patti · Ospedale Policlinico San Martino10 papers (2015–2019)Marek Postula · Longevity Biotech (United States)9 papers (2019–2026)Harald Sourij · University of Colorado Denver9 papers (2020–2026)Kurt Huber · FWF Austrian Science Fund8 papers (2015–2023)Kurt Huber · RHI Magnesita (Austria)8 papers (2019–2023) · 8 papers (2017–2019) · 8 papers (2017–2019)Paulus Kirchhof · Universität Hamburg7 papers (2017–2019)Diana A. Gorog · CHA Bundang Medical Center7 papers (2019–2023)Raffaele De Caterina · Radboud University Medical Center6 papers (2017–2019)Ceren Eyileten · Warsaw University of Life Sciences6 papers (2020–2026) · 5 papers (2018–2019)Mariusz Gąsior · Medical University of Silesia5 papers (2020–2025)Paulus Kirchhof · Amsterdam University Medical Centers5 papers (2019–2024)Zofia Wicik · Universidade Federal do ABC5 papers (2020–2026)Raffaele De Caterina · Radboud University Medical Center5 papers (2019–2023)